CTRI/2010/091/000433已完成2 期
Phase II study of Sunitinib as second line-treatment in advanced biliary tract carcinoma: multicentre, multinational study
Samsung Medical Centre0 个研究点目标入组 59 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Age more tha 18 years
- •2 Histologically or cytologically confirmed adenocarcinoma of biliary tract
- •3 Unresectable or metastatic
- •4 ECOG performance status of 0 and 2
- •5 Measurable or evaluable lesion per RECIST criteria
- •6 Adequate marrow hepatic renal and cardiac functions
- •7 One prior treatment of cytotoxic chemotherapy including adjuvant treatment within 12 months
- •8 Provision of a signed written informed consent
排除标准
- •1. Severe co-morbid illness and/or active infections
- •2. Pregnant or lactating women
- •3. Active CNS metastases not controllable with radiotherapy of corticosteroids
- •4. Known history of hypersensitivity to study drugs
研究者
相似试验
已完成
2 期
Sunitinib as Second-line Treatment in Advanced Biliary Tract CarcinomaAdvanced Biliary Tract AdenocarcinomaNCT01082809Samsung Medical Center59
进行中（未招募）
1 期
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapsePatients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse (extensive or limited disease).MedDRA version: 9.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2006-002485-19-BEEORTC-European Organisation for Research and Treatment of Cancer48
尚未招募
2 期
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapsesmall cell lung cancer1003866610029107NL-OMON33984European Organisation for Research in Treatment of Cancer (EORTC)20
进行中（未招募）
不适用
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapsePatients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse (extensive or limited disease).MedDRA version: 9.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2006-002485-19-DEEORTC-European Organisation for Research and Treatment of Cancer48
进行中（未招募）
1 期
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapseEUCTR2006-002485-19-GBEORTC-European Organisation for Research and Treatment of Cancer48